{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=n-3+control&page=2",
    "query": {
      "intervention": "n-3 control",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=n-3+control&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T02:16:13.945Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03077477",
      "title": "Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Medication Toxicity",
        "Tolerance"
      ],
      "interventions": [
        {
          "name": "AMXT 1501",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aminex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2018-06-12",
      "completion_date": "2018-06-12",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03077477"
    },
    {
      "nct_id": "NCT02204709",
      "title": "Disease Risk Reduction and Omega-3 Rich Rainbow Trout (Fish for Health)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "2N Trout",
          "type": "OTHER"
        },
        {
          "name": "3N Trout",
          "type": "OTHER"
        },
        {
          "name": "Tilapia",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "USDA Grand Forks Human Nutrition Research Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "20 Years to 70 Years"
      },
      "enrollment_count": 29,
      "start_date": "2015-06",
      "completion_date": "2020-03-25",
      "has_results": false,
      "last_update_posted_date": "2022-08-04",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 1,
      "location_summary": "Grand Forks, North Dakota",
      "locations": [
        {
          "city": "Grand Forks",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204709"
    },
    {
      "nct_id": "NCT00746954",
      "title": "Buspirone as a Potential Treatment for Recurrent Central Apnea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Central Apnea",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "Buspirone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-09",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2016-03-14",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00746954"
    },
    {
      "nct_id": "NCT05875948",
      "title": "Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatorenal Syndrome",
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "R2R01",
          "type": "DRUG"
        },
        {
          "name": "Terlipressin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "River 2 Renal Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2023-06-30",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875948"
    },
    {
      "nct_id": "NCT02710500",
      "title": "rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dysferlinopathy"
      ],
      "interventions": [
        {
          "name": "rAAVrh74.MHCK7.DYSF.DV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-03",
      "completion_date": "2019-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02710500"
    },
    {
      "nct_id": "NCT01336738",
      "title": "Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "150 mg PF-04991532",
          "type": "DRUG"
        },
        {
          "name": "450 mg PF-04991532",
          "type": "DRUG"
        },
        {
          "name": "750 mg PF-04991532",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 266,
      "start_date": "2011-06",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-08-06",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 28,
      "location_summary": "Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 21 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336738"
    },
    {
      "nct_id": "NCT01482403",
      "title": "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Copegus",
          "type": "DRUG"
        },
        {
          "name": "Pegasys",
          "type": "DRUG"
        },
        {
          "name": "boceprevir",
          "type": "DRUG"
        },
        {
          "name": "mericitabine",
          "type": "DRUG"
        },
        {
          "name": "mericitabine placebo",
          "type": "DRUG"
        },
        {
          "name": "boceprevir placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2011-11",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2016-08-05",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 7,
      "location_summary": "Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more",
      "locations": [
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482403"
    },
    {
      "nct_id": "NCT05145452",
      "title": "n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Neuropathies"
      ],
      "interventions": [
        {
          "name": "Fish-oil derived n-3 polyunsaturated fatty acids",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 31,
      "start_date": "2021-01-14",
      "completion_date": "2023-06-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05145452"
    },
    {
      "nct_id": "NCT06315738",
      "title": "Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Necrotizing Enterocolitis"
      ],
      "interventions": [
        {
          "name": "ST266",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Noveome Biotherapeutics, formerly Stemnion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": "8 Weeks",
        "sex": "ALL",
        "summary": "2 Weeks to 8 Weeks"
      },
      "enrollment_count": 36,
      "start_date": "2024-08-19",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • New Haven, Connecticut • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06315738"
    },
    {
      "nct_id": "NCT01869764",
      "title": "Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ductal Breast Carcinoma in Situ",
        "Lobular Breast Carcinoma in Situ",
        "Male Breast Cancer",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "omega-3 fatty acid",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2013-11",
      "completion_date": "2018-07",
      "has_results": true,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-09-22T02:16:13.945Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01869764"
    }
  ]
}